N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Phase 2 N=12 rTMS To The Dorsolateral Prefrontal Cortex For Patients With Subjective Idiopathic Tinnitus. A Pilot Study
Tinnitus
Primary: Average Change (Baseline-End of Treatment) Tinnitus Handicap Inventory (THI) — 10.7 units on a scale
Phase 3 N=62 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia (CAH)
Primary: Adult Height Relative to General Population — -0.34; -0.6 Standard Deviation Score (SDS) units
N/A N=6 Feasibility Electrical Stimulation Study for Visual Hallucinations
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Steady State Visual Evoked Potential (ssVEP) — 1.725; 1.160; 1.180; 1.005 microvolts — p=0.10
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 3 N=18 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Adrenal Tumors
Primary: Increase in Catecholamine
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
N/A N=10 Transcranial Focused Ultrasound (tFUS) Modulation of Reward Network
Healthy
Primary: Resting State Functional Connectivity — 0.069; 0.160 z value
N/A N=80 Neuroimaging Attentional Impairment During Abstinence
Smoking
Primary: Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Inferior Frontal Gyri (IFG) During Sustained Attention Task on Satiated Day — -0.0023…
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 3 N=24 Treatment of Adrenal Insufficiency in Children
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Phase 2 N=5 Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Adrenal Hyperplasia, Congenital
Primary: Percent Difference in the Mean Log Transformed Area Under the Curve of 17-hydroxyprogesterone Between Regimens — 3.16; 3.91 Log Mean Area Under the Curve — p=0.09
N/A N=30 Evaluation of Etomidate on Adrenal Function in Trauma Patients
Adrenal Insufficiency
Primary: Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test